trastuzumab deruxtecan,Tucatinib
astrazeneca,merck,seagen
['biomarker', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'spotlight', 'tdxd', 'tucatinib']
her2 overexpression is the biomarker in spotlight! tucatinib/tras and now exciting data with tdxd for mcrc. #asco23
Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Passionate about clinical research, education and pt-prov communication. #gicancer #meded